Do analysts prefer ALBT or GTBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALBT or GTBP more profitable?

Company Net Margins Return on Equity Return on Assets Avalon GloboCare N/A N/A -74.36% GT Biopharma N/A N/A -102.03%

Do analysts prefer ALBT or LNAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALBT or LNAI more profitable?

Avalon GloboCare's return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Avalon GloboCare N/A N/A -74.36% Lunai Bioworks N/A -1,243.45% -1,617.76%

Do analysts prefer ANEB or ALBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ANEB or ALBT more profitable?

Avalon GloboCare's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Anebulo Pharmaceuticals N/A -74.57% -68.96% Avalon GloboCare N/A N/A -74.36%

Do analysts recommend ALBT or APLT?

Applied Therapeutics has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than Avalon GloboCare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is ALBT or APLT more profitable?

Avalon GloboCare's return on equity of 0.00% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalon GloboCare N/A N/A -74.36% Applied Therapeutics N/A -340.84% -175.00%

Do analysts prefer ALBT or CTXR?

Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 825.93%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Avalon GloboCare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is ALBT or CTXR more profitable?

Avalon GloboCare's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Avalon GloboCare N/A N/A -74.36% Citius Pharmaceuticals N/A -61.09% -35.36%

Avalon GloboCare (ALBT) Competitors

$0.28 -0.02 (-6.00%)

Closing price 04:00 PM Eastern

Extended Trading

$0.29 +0.01 (+4.26%)

As of 07:50 PM Eastern

Compare

ALBT vs. GTBP, LNAI, ANEB, APLT, and CTXR

Should you buy Avalon GloboCare stock or one of its competitors? MarketBeat compares Avalon GloboCare with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avalon GloboCare include GT Biopharma (GTBP), Lunai Bioworks (LNAI), Anebulo Pharmaceuticals (ANEB), Applied Therapeutics (APLT), and Citius Pharmaceuticals (CTXR). These companies are all part of the "pharmaceutical products" industry.

How does Avalon GloboCare compare to GT Biopharma?

Avalon GloboCare (NASDAQ:ALBT) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Avalon GloboCare has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Avalon GloboCare has higher revenue and earnings than GT Biopharma. Avalon GloboCare is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26M	2.70	-$18.26M	-$3.51	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

In the previous week, GT Biopharma had 2 more articles in the media than Avalon GloboCare. MarketBeat recorded 3 mentions for GT Biopharma and 1 mentions for Avalon GloboCare. Avalon GloboCare's average media sentiment score of 1.89 beat GT Biopharma's score of 0.50 indicating that Avalon GloboCare is being referred to more favorably in the media.

Company	Overall Sentiment
Avalon GloboCare	Very Positive
GT Biopharma	Positive

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
GT Biopharma	N/A	N/A	-102.03%

1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 8.2% of GT Biopharma shares are held by institutional investors. 24.2% of Avalon GloboCare shares are held by company insiders. Comparatively, 3.4% of GT Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Avalon GloboCare beats GT Biopharma on 6 of the 10 factors compared between the two stocks.

How does Avalon GloboCare compare to Lunai Bioworks?

Avalon GloboCare (NASDAQ:ALBT) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Avalon GloboCare and Avalon GloboCare both had 1 articles in the media. Avalon GloboCare's average media sentiment score of 1.89 beat Lunai Bioworks' score of 1.87 indicating that Avalon GloboCare is being referred to more favorably in the media.

Company	Overall Sentiment
Avalon GloboCare	Very Positive
Lunai Bioworks	Very Positive

Avalon GloboCare's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Avalon GloboCare has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are owned by institutional investors. 24.2% of Avalon GloboCare shares are owned by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Avalon GloboCare has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26M	2.70	-$18.26M	-$3.51	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

Summary

Avalon GloboCare beats Lunai Bioworks on 7 of the 10 factors compared between the two stocks.

How does Avalon GloboCare compare to Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Avalon GloboCare's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Avalon GloboCare	N/A	N/A	-74.36%

Anebulo Pharmaceuticals has a beta of -1.88, suggesting that its stock price is 288% less volatile than the broader market. Comparatively, Avalon GloboCare has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anebulo Pharmaceuticals has higher earnings, but lower revenue than Avalon GloboCare. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Avalon GloboCare	$1.26M	2.70	-$18.26M	-$3.51	N/A

In the previous week, Avalon GloboCare had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 1 mentions for Avalon GloboCare and 0 mentions for Anebulo Pharmaceuticals. Avalon GloboCare's average media sentiment score of 1.89 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Avalon GloboCare is being referred to more favorably in the news media.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
Avalon GloboCare	Very Positive

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Comparatively, 24.2% of Avalon GloboCare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Anebulo Pharmaceuticals and Avalon GloboCare tied by winning 6 of the 12 factors compared between the two stocks.

How does Avalon GloboCare compare to Applied Therapeutics?

Avalon GloboCare (NASDAQ:ALBT) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Avalon GloboCare has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

Avalon GloboCare has higher revenue and earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26M	2.70	-$18.26M	-$3.51	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 24.2% of Avalon GloboCare shares are owned by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Avalon GloboCare had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for Avalon GloboCare and 0 mentions for Applied Therapeutics. Avalon GloboCare's average media sentiment score of 1.89 beat Applied Therapeutics' score of 0.00 indicating that Avalon GloboCare is being referred to more favorably in the media.

Company	Overall Sentiment
Avalon GloboCare	Very Positive
Applied Therapeutics	Neutral

Avalon GloboCare's return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
Applied Therapeutics	N/A	-340.84%	-175.00%

Applied Therapeutics has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than Avalon GloboCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Avalon GloboCare beats Applied Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Avalon GloboCare compare to Citius Pharmaceuticals?

Avalon GloboCare (NASDAQ:ALBT) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Avalon GloboCare has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Avalon GloboCare's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

Avalon GloboCare has higher revenue and earnings than Citius Pharmaceuticals. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26M	2.70	-$18.26M	-$3.51	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 825.93%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Avalon GloboCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 24.2% of Avalon GloboCare shares are owned by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Avalon GloboCare and Avalon GloboCare both had 1 articles in the media. Avalon GloboCare's average media sentiment score of 1.89 beat Citius Pharmaceuticals' score of 1.87 indicating that Avalon GloboCare is being referred to more favorably in the media.

Company	Overall Sentiment
Avalon GloboCare	Very Positive
Citius Pharmaceuticals	Very Positive

Summary

Citius Pharmaceuticals beats Avalon GloboCare on 7 of the 13 factors compared between the two stocks.

Get Avalon GloboCare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALBT vs. The Competition

Export

Metric	Avalon GloboCare	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.61M	$3.56B	$6.71B	$12.23B
Dividend Yield	N/A	2.25%	2.67%	6.10%
P/E Ratio	-0.08	21.56	26.03	24.18
Price / Sales	2.70	337.10	556.43	100.98
Price / Cash	N/A	137.38	46.99	54.37
Price / Book	-0.07	8.34	10.77	6.35
Net Income	-$18.26M	$23.91M	$3.57B	$337.63M
7 Day Performance	-17.06%	6.87%	3.15%	-0.30%
1 Month Performance	-21.67%	5.53%	2.33%	0.36%
1 Year Performance	-91.85%	62.60%	33.42%	26.94%

Avalon GloboCare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALBT Avalon GloboCare	0.8663 of 5 stars	$0.28 -6.0%	N/A	-91.3%	$3.61M	$1.26M	N/A	5
GTBP GT Biopharma	0.5333 of 5 stars	$0.46 -7.2%	N/A	-87.6%	$16.52M	N/A	N/A	8	Gap Up
LNAI Lunai Bioworks	0.508 of 5 stars	$3.60 -16.4%	N/A	N/A	$16.31M	N/A	N/A	20	Positive News
ANEB Anebulo Pharmaceuticals	N/A	$0.40 -0.2%	N/A	-73.1%	$16.11M	N/A	N/A	4
APLT Applied Therapeutics	1.4401 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALBT) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalon GloboCare (ALBT) Competitors

ALBT vs. GTBP, LNAI, ANEB, APLT, and CTXR

How does Avalon GloboCare compare to GT Biopharma?

Summary

How does Avalon GloboCare compare to Lunai Bioworks?

Summary

How does Avalon GloboCare compare to Anebulo Pharmaceuticals?

Summary

How does Avalon GloboCare compare to Applied Therapeutics?

Summary

How does Avalon GloboCare compare to Citius Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALBT vs. The Competition

Avalon GloboCare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalon GloboCare (ALBT) Competitors

ALBT vs. GTBP, LNAI, ANEB, APLT, and CTXR

How does Avalon GloboCare compare to GT Biopharma?

Which has more volatility and risk, ALBT or GTBP?

Which has better earnings and valuation, ALBT or GTBP?

Does the media favor ALBT or GTBP?

Is ALBT or GTBP more profitable?

Do insiders & institutionals hold more shares of ALBT or GTBP?

Do analysts prefer ALBT or GTBP?

Summary

How does Avalon GloboCare compare to Lunai Bioworks?

Does the media favor ALBT or LNAI?

Is ALBT or LNAI more profitable?

Do analysts prefer ALBT or LNAI?

Which has more volatility & risk, ALBT or LNAI?

Do insiders and institutionals have more ownership in ALBT or LNAI?

Which has preferable earnings and valuation, ALBT or LNAI?

Summary

How does Avalon GloboCare compare to Anebulo Pharmaceuticals?

Is ANEB or ALBT more profitable?

Which has more risk and volatility, ANEB or ALBT?

Do analysts prefer ANEB or ALBT?

Which has preferable earnings & valuation, ANEB or ALBT?

Does the media refer more to ANEB or ALBT?

Do insiders & institutionals hold more shares of ANEB or ALBT?

Summary

How does Avalon GloboCare compare to Applied Therapeutics?

Which has more risk and volatility, ALBT or APLT?

Which has stronger valuation & earnings, ALBT or APLT?

Do insiders and institutionals have more ownership in ALBT or APLT?

Does the media refer more to ALBT or APLT?

Is ALBT or APLT more profitable?

Do analysts recommend ALBT or APLT?

Summary

How does Avalon GloboCare compare to Citius Pharmaceuticals?

Which has more risk & volatility, ALBT or CTXR?

Is ALBT or CTXR more profitable?

Which has stronger earnings & valuation, ALBT or CTXR?

Do analysts prefer ALBT or CTXR?

Do institutionals and insiders have more ownership in ALBT or CTXR?

Does the media favor ALBT or CTXR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALBT vs. The Competition

Avalon GloboCare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools